By analyzing NANOG and the antitumor immune state signature in transcriptomic data on patients with melanoma classified as responders or nonresponders to anti–PD-1 treatment (33), we found that the antitumor immune state signature scores were significantly lower in nonresponders than in responders (Supplemental Figure 1). This evidence concerns the gene PDCD1 and melanoma.